Two New Warnings from the FDA on MS Medications
- Gilenya (fingolimod): Drug Safety Communication - Severe Worsening of Multiple Sclerosis After Stopping the Medicine. U.S. Food and Drug Administration. Available at https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm626264.htm. Accessed 12/11/18.
- FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab). U.S. Food and Drug Administration. Available at https://www.fda.gov/Drugs/DrugSafety/ucm624247.htm. Accessed 12/11/18.